|Real-world results from the largest analyses of Vertex Pharmaceutical’s cystic fibrosis’ treatment Kalydeco (ivacaftor) done in CF patients to date confirm the therapy’s ability to significantly lower the risks of mortality, transplants, hospitalization, and pulmonary exacerbations compared to untreated patients. These results were presented today at the 41st European Cystic Fibrosis Society (ECFS) Conference, taking place through June 9 […]|
The post #ECFS2018 – Kalydeco’s Benefits Include Lower Risk of Death and Pulmonary Flares, Real-world Data Shows appeared first on Cystic Fibrosis News Today.
VIRTUD | Thuk Je Che Tibet - Inicio
Hace 1 hora